Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Engasertib in Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
NCT07743671Phase 3Recruiting
- Sponsor
- Vaderis Therapeutics AG
- Start
- Sep 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
A Phase 3 trial of engasertib in hereditary hemorrhagic telangiectasia (HHT), sponsored by Vaderis Therapeutics AG. Started Sep 2026; status: recruiting.
02
Drugs
engasertib
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT07743671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743671.